Anti-inflammatory steroids from the soft coral Cladiella sp.

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-02-17 DOI:10.1016/j.phytol.2025.02.006

Wen Wen , Delan Yang , Hao Wang , Huiqin Chen , Yanbo Zeng

引用次数: 0

Abstract

A new undescribed steroid 23,24-epoxy-24-methylchol-5-ene-3β-ol (1), together with two known steroids (24S)-24-methylcholest-5-ene-3β,25-diol (2) and 16-hydroxysarcosterol (3) was extracted from the soft coral Cladiella sp. Their structures were investigated by IR, MS, 1D and 2D NMR spectra, while QM-NMR calculations were utilized to ascertain the configuration of compound 1. The potential anti-inflammatory properties of all compounds were assessed. Compound 1 exerted a moderate suppressive effect on LPS-stimulated inflammatory reactions in RAW264.7 macrophage cells, with IC₅₀ value of 32.93 ± 2.32 μM. Compounds 2 and 3 demonstrated weaker inhibitory effects, with IC₅₀ values of 80.05 ± 7.11 and 54.05 ± 2.82 μM, respectively.

查看原文本刊更多论文

软珊瑚Cladiella sp.的抗炎类固醇。

从软珊瑚Cladiella sp中提取了一种新的未描述的甾体23,24-环氧-24-甲基胆-5-烯-3β- 1(1)，以及两种已知的甾体(24S)-24-甲基胆-5-烯-3β，25-二醇(2)和16-羟基糖甾醇(3)。通过IR， MS， 1D和2D NMR对它们的结构进行了研究，并利用QM-NMR计算确定了化合物1的构型。评估了所有化合物的潜在抗炎特性。化合物1对lps刺激的RAW264.7巨噬细胞炎症反应具有中等抑制作用，IC50值为32.93 ± 2.32 μM。化合物2和3的抑制作用较弱，IC50值分别为80.05 ± 7.11和54.05 ± 2.82 μM。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.